Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Albumin Therapy for Recurrent Ascites in Decompensated Cirrhosis
NCT04679571Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Dec 2020
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of albumin (human) in decompensated cirrhosis and ascites (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Mortality at 6 months. Status: unknown.
02
Drugs
albumin (human)
03
Conditions
decompensated cirrhosisascites
Beyond the preview
Go deeper on NCT04679571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679571.